Login Register Cart 0
Review Article

肥胖治疗:如何和为什么？

卷 27, 期 2, 2020

页: [174 - 186] 页: 13

弟呕挨: 10.2174/0929867326666190124121725

价格: $65

摘要

背景: 肥胖是全球第二大可预防的死亡原因，通常与2型糖尿病(T2DM)有关。一线治疗是通过改变生活方式来达到减肥的目的，但对于那些没有达到目标或难以维持已达到效果的患者，则需要进行药物治疗。由于药物的副作用，现在市面上减肥的药物很少。 目的: 我们的目标是回顾肥胖患者的实际药理学管理，强调美国食品和药物管理局和欧洲药物管理局批准的分子之间的差异，并指出自我药物容易获得和广泛分布。 方法: 运用Medline数据库，对肥胖、减肥、药物治疗、自我用药、节食产品等方面的论文进行筛选。筛选研究文章、系统综述、临床试验和荟萃分析。 结果: 作用于中枢的减肥药物，如芬特明和罗卡西林，在美国市面上有，但在欧洲没有。芬特明/托吡酯和纳曲酮/安非他酮组合现在已经上市，尽管前者仍在欧洲药品管理局（EMA）的监测当中。奥利司他，具有外周机制，是唯一被批准用于青少年减肥的药物。利拉鲁肽已被批准用于治疗肥胖。

关键词: 肥胖，2型糖尿病，药理学，作用机制，自我药疗，膳食补充剂。

« Previous Next »
[1]
Massimo, C. Eating Disorders and Obesity in: Clinical Management of Overweight and Obesity. Recommendations of the Italian. Society of Obesity (SIO); Sbraccia, P. Nisoli, E.; Vettor, R. (Eds.); Springer International Publishing, 2016, pp. 103-123.
[http://dx.doi.org/10.1007/978-3-319-24532-4]
[2]
Bray, G.A. Why do we need drugs to treat the patient with obesity? Obesity (Silver Spring), 2013, 21(5), 893-899.
[http://dx.doi.org/10.1002/oby.20394] [PMID: 23520198]
[3]
Gadde, K.M.; Pritham Raj, Y. Pharmacotherapy of obesity: clinical trials to clinical practice. Curr. Diab. Rep., 2017, 17(5), 34.
[http://dx.doi.org/10.1007/s11892-017-0859-2] [PMID: 28378293]
[4]
Flier, J.S. Obesity wars: molecular progress confronts an expanding epidemic. Cell, 2004, 116(2), 337-350.
[http://dx.doi.org/10.1016/S0092-8674(03)01081-X] [PMID: 14744442]
[5]
Kim, J.D.; Leyva, S.; Diano, S. Hormonal regulation of the hypothalamic melanocortin system. Front. Physiol., 2014, 5, 480.
[http://dx.doi.org/10.3389/fphys.2014.00480] [PMID: 25538630]
[6]
Gao, X.B.; Hermes, G. Neural plasticity in hypocretin neurons: the basis of hypocretinergic regulation of physiological and behavioral functions in animals. Front. Syst. Neurosci., 2015, 9, 142.
[http://dx.doi.org/10.3389/fnsys.2015.00142] [PMID: 26539086]
[7]
Norton, M.; Murphy, K.G. Targeting gastrointestinal nutrient sensing mechanisms to treat obesity. Curr. Opin. Pharmacol., 2017, 37, 16-23.
[http://dx.doi.org/10.1016/j.coph.2017.07.005] [PMID: 28802874]
[8]
Heisler, L.K.; Lam, D.D. An appetite for life: brain regulation of hunger and satiety. Curr. Opin. Pharmacol., 2017, 37, 100-106.
[http://dx.doi.org/10.1016/j.coph.2017.09.002] [PMID: 29107871]
[9]
Burger, K.S.; Berner, L.A. A functional neuroimaging review of obesity, appetitive hormones and ingestive behavior. Physiol. Behav., 2014, 136, 121-127.
[http://dx.doi.org/10.1016/j.physbeh.2014.04.025] [PMID: 24769220]
[10]
Adan, R.A. Mechanisms underlying current and future anti-obesity drugs. Trends Neurosci., 2013, 36(2), 133-140.
[http://dx.doi.org/10.1016/j.tins.2012.12.001] [PMID: 23312373]
[11]
Leibowitz, S.F.; Alexander, J.T. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol. Psychiatry, 1998, 44(9), 851-864.
[http://dx.doi.org/10.1016/S0006-3223(98)00186-3] [PMID: 9807640]
[12]
Berridge, K.C. ‘Liking’ and ‘wanting’ food rewards: brain substrates and roles in eating disorders. Physiol. Behav., 2009, 97(5), 537-550.
[http://dx.doi.org/10.1016/j.physbeh.2009.02.044] [PMID: 19336238]
[13]
Chen, Y. Regulation of food intake and the development of anti-obesity drugs. Drug Discov. Ther., 2016, 10(2), 62-73.
[http://dx.doi.org/10.5582/ddt.2016.01014] [PMID: 27063550]
[14]
Aronne, L.J.; Wadden, T.A.; Peterson, C.; Winslow, D.; Odeh, S.; Gadde, K.M. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring), 2013, 21(11), 2163-2171.
[http://dx.doi.org/10.1002/oby.20584] [PMID: 24136928]
[15]
Munro, J.F.; MacCuish, A.C.; Wilson, E.M.; Duncan, L.J. Comparison of continuous and intermittent anorectic therapy in obesity. BMJ, 1968, 1(5588), 352-354.
[http://dx.doi.org/10.1136/bmj.1.5588.352] [PMID: 15508204]
[16]
Verrotti, A.; Scaparrotta, A.; Agostinelli, S.; Di Pillo, S.; Chiarelli, F.; Grosso, S. Topiramate-induced weight loss: a review. Epilepsy Res., 2011, 95(3), 189-199.
[http://dx.doi.org/10.1016/j.eplepsyres.2011.05.014] [PMID: 21684121]
[17]
Kiortsis, D.N. A review of the metabolic effects of controlled-release Phentermine/Topiramate. Hormones (Athens), 2013, 12(4), 507-516.
[http://dx.doi.org/10.14310/horm.2002.1438] [PMID: 24457398]
[18]
Fleming, J.W.; McClendon, K.S.; Riche, D.M. New obesity agents: lorcaserin and phentermine/topiramate. Ann. Pharmacother., 2013, 47(7-8), 1007-1016.
[http://dx.doi.org/10.1345/aph.1R779] [PMID: 23800750]
[19]
Hess, R.; Cross, L.B. The safety and efficacy of lorcaserin in the management of obesity. Postgrad. Med., 2013, 125(6), 62-72.
[http://dx.doi.org/10.3810/pgm.2013.11.2713] [PMID: 24200762]
[20]
Greenway, F.L.; Fujioka, K.; Plodkowski, R.A.; Mudaliar, S.; Guttadauria, M.; Erickson, J.; Kim, D.D.; Dunayevich, E. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2010, 376(9741), 595-605.
[http://dx.doi.org/10.1016/S0140-6736(10)60888-4] [PMID: 20673995]
[21]
Apovian, C.M.; Aronne, L.; Rubino, D.; Still, C.; Wyatt, H.; Burns, C.; Kim, D.; Dunayevich, E. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring), 2013, 21(5), 935-943.
[http://dx.doi.org/10.1002/oby.20309] [PMID: 23408728]
[22]
Wadden, T.A.; Foreyt, J.P.; Foster, G.D.; Hill, J.O.; Klein, S.; O’Neil, P.M.; Perri, M.G.; Pi-Sunyer, F.X.; Rock, C.L.; Erickson, J.S.; Maier, H.N.; Kim, D.D.; Dunayevich, E. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring), 2011, 19(1), 110-120.
[http://dx.doi.org/10.1038/oby.2010.147] [PMID: 20559296]
[23]
Hollander, P.; Gupta, A.K.; Plodkowski, R.; Greenway, F.; Bays, H.; Burns, C.; Klassen, P.; Fujioka, K. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care, 2013, 36(12), 4022-4029.
[http://dx.doi.org/10.2337/dc13-0234] [PMID: 24144653]
[24]
Halseth, A.; Shan, K.; Walsh, B.; Gilder, K.; Fujioka, K. Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. Obesity (Silver Spring), 2017, 25(2), 338-345.
[http://dx.doi.org/10.1002/oby.21726] [PMID: 28026920]
[25]
Baggio, L.L.; Drucker, D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology, 2007, 132(6), 2131-2157.
[http://dx.doi.org/10.1053/j.gastro.2007.03.054] [PMID: 17498508]
[26]
Rotella, C.M.; Pala, L.; Mannucci, E. Glucagon-like peptide 1 (GLP-1) and metabolic diseases. J. Endocrinol. Invest., 2005, 28(8), 746-758.
[http://dx.doi.org/10.1007/BF03347560] [PMID: 16277173]
[27]
Pala, L.; Mannucci, E.; Pezzatini, A.; Ciani, S.; Sardi, J.; Raimondi, L.; Ognibene, A.; Cappadona, A.; Vannelli, B.G.; Rotella, C.M. Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem. Biophys. Res. Commun., 2003, 310(1), 28-31.
[http://dx.doi.org/10.1016/j.bbrc.2003.08.111] [PMID: 14511643]
[28]
Troke, R.C.; Tan, T.M.; Bloom, S.R. The future role of gut hormones in the treatment of obesity. Ther. Adv. Chronic Dis., 2014, 5(1), 4-14.
[http://dx.doi.org/10.1177/2040622313506730] [PMID: 24381724]
[29]
Nyborg, N.C.; Mølck, A.M.; Madsen, L.W.; Knudsen, L.B. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes, 2012, 61(5), 1243-1249.
[http://dx.doi.org/10.2337/db11-0936] [PMID: 22338093]
[30]
Knudsen, L.B.; Nielsen, P.F.; Huusfeldt, P.O.; Johansen, N.L.; Madsen, K.; Pedersen, F.Z.; Thøgersen, H.; Wilken, M.; Agersø, H. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem., 2000, 43(9), 1664-1669.
[http://dx.doi.org/10.1021/jm9909645] [PMID: 10794683]
[31]
Ostawal, A.; Mocevic, E.; Kragh, N.; Xu, W. Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review. Diabetes Ther., 2016, 7(3), 411-438.
[http://dx.doi.org/10.1007/s13300-016-0180-0] [PMID: 27350545]
[32]
Astrup, A.; Rössner, S.; Van Gaal, L.; Rissanen, A.; Niskanen, L.; Al Hakim, M.; Madsen, J.; Rasmussen, M.F.; Lean, M.E. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet, 2009, 374(9701), 1606-1616.
[http://dx.doi.org/10.1016/S0140-6736(09)61375-1] [PMID: 19853906]
[33]
Lowe, M.E. Pancreatic triglyceride lipase and colipase: insights into dietary fat digestion. Gastroenterology, 1994, 107(5), 1524-1536.
[http://dx.doi.org/10.1016/0016-5085(94)90559-2] [PMID: 7926517]
[34]
Iqbal, J.; Hussain, M.M. Intestinal lipid absorption. Am. J. Physiol. Endocrinol. Metab., 2009, 296(6), E1183-E1194.
[http://dx.doi.org/10.1152/ajpendo.90899.2008] [PMID: 19158321]
[35]
Mattson, F.H.; Volpenhein, R.A. THE DIGESTION AND ABSORPTION OF TRIGLYCERIDES. J. Biol. Chem., 1964, 239, 2772-2777.
[PMID: 14216426]
[36]
Mu, H.; Høy, C.E. The digestion of dietary triacylglycerols. Prog. Lipid Res., 2004, 43(2), 105-133.
[http://dx.doi.org/10.1016/S0163-7827(03)00050-X] [PMID: 14654090]
[37]
Masson, C.J.; Plat, J.; Mensink, R.P.; Namiot, A.; Kisielewski, W.; Namiot, Z.; Füllekrug, J.; Ehehalt, R.; Glatz, J.F.; Pelsers, M.M. Fatty acid- and cholesterol transporter protein expression along the human intestinal tract. PLoS One, 2010, 5(4)e10380
[http://dx.doi.org/10.1371/journal.pone.0010380] [PMID: 20454462]
[38]
Luiken, J.J.; Koonen, D.P.; Coumans, W.A.; Pelsers, M.M.; Binas, B.; Bonen, A.; Glatz, J.F. Long-chain fatty acid uptake by skeletal muscle is impaired in homozygous, but not heterozygous, heart-type-FABP null mice. Lipids, 2003, 38(4), 491-496.
[http://dx.doi.org/10.1007/s11745-003-1089-6] [PMID: 12848299]
[39]
Borgstrom, B. Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim. Biophys. Acta, 1988, 962(3), 308-316.
[http://dx.doi.org/10.1016/0005-2760(88)90260-3] [PMID: 3167082]
[40]
Weibel, E.K.; Hadvary, P.; Hochuli, E.; Kupfer, E.; Lengsfeld, H. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity. J. Antibiot. (Tokyo), 1987, 40(8), 1081-1085.
[http://dx.doi.org/10.7164/antibiotics.40.1081] [PMID: 3680018]
[41]
Hogan, S.; Fleury, A.; Hadvary, P.; Lengsfeld, H.; Meier, M.K.; Triscari, J.; Sullivan, A.C. Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase. Int. J. Obes., 1987, 11(Suppl. 3), 35-42.
[PMID: 3440690]
[42]
Barbier, P.; Schneider, F. Syntheses of Tetrahydrolipstatin and Absolute Configuration of Tetrahydrolipstatin and Lipstatin. Helv. Chim. Acta, 1987, 70(1), 196-202.
[http://dx.doi.org/10.1002/hlca.19870700124]
[43]
Zhi, J.; Melia, A.T.; Eggers, H.; Joly, R.; Patel, I.H. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J. Clin. Pharmacol., 1995, 35(11), 1103-1108.
[http://dx.doi.org/10.1002/j.1552-4604.1995.tb04034.x] [PMID: 8626884]
[44]
Zhi, J.; Melia, A.T.; Guerciolini, R.; Chung, J.; Kinberg, J.; Hauptman, J.B.; Patel, I.H. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin. Pharmacol. Ther., 1994, 56(1), 82-85.
[http://dx.doi.org/10.1038/clpt.1994.104] [PMID: 8033498]
[45]
Sjöström, L.; Rissanen, A.; Andersen, T.; Boldrin, M.; Golay, A.; Koppeschaar, H.P.; Krempf, M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet, 1998, 352(9123), 167-172.
[http://dx.doi.org/10.1016/S0140-6736(97)11509-4] [PMID: 9683204]
[46]
Kelley, D.E.; Jneidi, M. Orlistat in the treatment of Type 2 diabetes mellitus. Expert Opin. Pharmacother., 2002, 3(5), 599-605.
[http://dx.doi.org/10.1517/14656566.3.5.599] [PMID: 11996637]
[47]
Miles, J.M.; Leiter, L.; Hollander, P.; Wadden, T.; Anderson, J.W.; Doyle, M.; Foreyt, J.; Aronne, L.; Klein, S. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care, 2002, 25(7), 1123-1128.
[http://dx.doi.org/10.2337/diacare.25.7.1123] [PMID: 12087008]
[48]
Padwal, R.; Li, S.K.; Lau, D.C. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int. J. Obes. Relat. Metab. Disord., 2003, 27(12), 1437-1446.
[http://dx.doi.org/10.1038/sj.ijo.0802475] [PMID: 12975638]
[49]
Sahebkar, A.; Simental-Mendía, L.E.; Reiner, Ž.; Kovanen, P.T.; Simental-Mendía, M.; Bianconi, V.; Pirro, M. Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials. Pharmacol. Res., 2017, 122, 53-65.
[http://dx.doi.org/10.1016/j.phrs.2017.05.022] [PMID: 28559211]
[50]
Khera, R.; Pandey, A.; Chandar, A.K.; Murad, M.H.; Prokop, L.J.; Neeland, I.J.; Berry, J.D.; Camilleri, M.; Singh, S. Effects of weight-loss medications on cardiometabolic risk profiles: a systematic review and network meta-analysis. Gastroenterology, 2018, 154(5), 1309-1319, e7.
[http://dx.doi.org/10.1053/j.gastro.2017.12.024] [PMID: 29305933]
[51]
Mannucci, E.; Dicembrini, I.; Rotella, F.; Rotella, C.M. Orlistat and sibutramine beyond weight loss. Nutr. Metab. Cardiovasc. Dis., 2008, 18(5), 342-348.
[http://dx.doi.org/10.1016/j.numecd.2007.03.010] [PMID: 17928208]
[52]
Song, J.; Ruan, X.; Gu, M.; Wang, L.; Wang, H.; Mueck, A.O. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecol. Endocrinol., 2018, 34(5), 413-417.
[http://dx.doi.org/10.1080/09513590.2017.1407752] [PMID: 29172796]
[53]
Ogden, C.L.; Carroll, M.D.; Kit, B.K.; Flegal, K.M. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA, 2014, 311(8), 806-814.
[http://dx.doi.org/10.1001/jama.2014.732] [PMID: 24570244]
[54]
Wijnhoven, T.M.; van Raaij, J.M.; Spinelli, A.; Starc, G.; Hassapidou, M.; Spiroski, I.; Rutter, H.; Martos, É.; Rito, A.I.; Hovengen, R.; Pérez-Farinós, N.; Petrauskiene, A.; Eldin, N.; Braeckevelt, L.; Pudule, I.; Kunešová, M.; Breda, J. WHO European Childhood Obesity Surveillance Initiative: body mass index and level of overweight among 6-9-year-old children from school year 2007/2008 to school year 2009/2010. BMC Public Health, 2014, 14, 806.
[http://dx.doi.org/10.1186/1471-2458-14-806] [PMID: 25099430]
[55]
Lazzeri, G.; Giacchi, M.V.; Spinelli, A.; Pammolli, A.; Dalmasso, P.; Nardone, P.; Lamberti, A.; Cavallo, F. Overweight among students aged 11-15 years and its relationship with breakfast, area of residence and parents’ education: results from the Italian HBSC 2010 cross-sectional study. Nutr. J., 2014, 13, 69.
[http://dx.doi.org/10.1186/1475-2891-13-69] [PMID: 24997676]
[56]
Rajjo, T.; Mohammed, K.; Alsawas, M.; Ahmed, A.T.; Farah, W.; Asi, N.; Almasri, J.; Prokop, L.J.; Murad, M.H. Treatment of pediatric obesity: an umbrella systematic review. J. Clin. Endocrinol. Metab., 2017, 102(3), 763-775.
[http://dx.doi.org/10.1210/jc.2016-2574] [PMID: 28359101]
[57]
Gupta, A.K.; Nasothimiou, E.G.; Chang, C.L.; Sever, P.S.; Dahlöf, B.; Poulter, N.R. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J. Hypertens., 2011, 29(10), 2004-2013.
[http://dx.doi.org/10.1097/HJH.0b013e32834a8a42] [PMID: 21881528]
[58]
Derosa, G.; Cicero, A.F.; D’Angelo, A.; Fogari, E.; Maffioli, P. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. J. Clin. Pharm. Ther., 2012, 37(2), 187-195.
[http://dx.doi.org/10.1111/j.1365-2710.2011.01280.x] [PMID: 21812797]
[59]
Aldekhail, N.M.; Logue, J.; McLoone, P.; Morrison, D.S. Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Obes. Rev., 2015, 16(12), 1071-1080.
[http://dx.doi.org/10.1111/obr.12318] [PMID: 26345590]
[60]
Jacob, S.; Rabbia, M.; Meier, M.K.; Hauptman, J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes. Metab., 2009, 11(4), 361-371.
[http://dx.doi.org/10.1111/j.1463-1326.2008.00970.x] [PMID: 19207292]
[61]
Cheung, B.M.; Cheung, T.T.; Samaranayake, N.R. Safety of antiobesity drugs. Ther. Adv. Drug Saf., 2013, 4(4), 171-181.
[http://dx.doi.org/10.1177/2042098613489721] [PMID: 25114779]
[62]
Solomon, L.R.; Nixon, A.C.; Ogden, L.; Nair, B. Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease. BMJ Case Rep, 2017, 2017, pii: bcr-2016-218623.
[http://dx.doi.org/10.1136/bcr-2016-218623] [PMID: 29133578]
[63]
Esteghamati, A.; Mazaheri, T.; Vahidi Rad, M.; Noshad, S. Complementary and alternative medicine for the treatment of obesity: a critical review. Int. J. Endocrinol. Metab., 2015, 13(2)e19678
[http://dx.doi.org/10.5812/ijem.19678] [PMID: 25892995]
[64]
Blank, S.E.; Johnson, E.C.; Weeks, D.K.; Wysham, C.H. Circulating dendritic cell number and intracellular TNF-α production in women with type 2 diabetes. Acta Diabetol., 2012, 49(Suppl. 1), S25-S32.
[http://dx.doi.org/10.1007/s00592-010-0190-8] [PMID: 20449757]
[65]
Khan, M.H.; Tanimoto, T.; Nakanishi, Y.; Yoshida, N.; Tsuboi, H.; Kimura, K. Public health concerns for anti-obesity medicines imported for personal use through the internet: a cross-sectional study. BMJ Open, 2012, 2(3)e000854
[http://dx.doi.org/10.1136/bmjopen-2012-000854] [PMID: 22581794]
[66]
Ronis, M.J.J.; Pedersen, K.B.; Watt, J. Adverse effects of nutraceuticals and dietary supplements. Annu. Rev. Pharmacol. Toxicol., 2018, 58, 583-601.
[http://dx.doi.org/10.1146/annurev-pharmtox-010617-052844] [PMID: 28992429]
[67]
Fan, Y.; Adam, T.J.; McEwan, R.; Pakhomov, S.V.; Melton, G.B.; Zhang, R. Detecting signals of interactions between warfarin and dietary supplements in electronic health records. Stud. Health Technol. Inform., 2017, 245, 370-374.
[PMID: 29295118]
[68]
Sharpe, P.A.; Granner, M.L.; Conway, J.M.; Ainsworth, B.E.; Dobre, M. Availability of weight-loss supplements: Results of an audit of retail outlets in a southeastern city. J. Am. Diet. Assoc., 2006, 106(12), 2045-2051.
[http://dx.doi.org/10.1016/j.jada.2006.09.014] [PMID: 17126636]
[69]
Chan, T.Y. Potential risks associated with the use of herbal anti-obesity products. Drug Saf., 2009, 32(6), 453-456.
[http://dx.doi.org/10.2165/00002018-200932060-00002] [PMID: 19459713]
[70]
Cohen, P.A.; Travis, J.C.; Keizers, P.H.J.; Deuster, P.; Venhuis, B.J. Four experimental stimulants found in sports and weight loss supplements: 2-amino-6-methylheptane (octodrine), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylamylamine (1,3-DMAA) and 1,3-dimethylbutylamine (1,3-DMBA). Clin. Toxicol. (Phila.), 2018, 56(6), 421-426.
[http://dx.doi.org/10.1080/15563650.2017.1398328] [PMID: 29115866]
[71]
Dos Santos, V.B.; Daniel, D.; Singh, M.; do Lago, C.L. Amphetamine and derivatives in natural weight loss pills and dietary supplements by capillary electrophoresis-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2016, 1038, 19-25.
[http://dx.doi.org/10.1016/j.jchromb.2016.10.019] [PMID: 27776329]
[72]
Yoshida, N.; Numano, M.; Nagasaka, Y.; Ueda, K.; Tsuboi, H.; Tanimoto, T.; Kimura, K. Study on health hazards through medicines purchased on the Internet: a cross-sectional investigation of the quality of anti-obesity medicines containing crude drugs as active ingredients. BMC Complement. Altern. Med., 2015, 15(1), 430.
[http://dx.doi.org/10.1186/s12906-015-0955-2] [PMID: 26637485]
[73]
Hasani-Ranjbar, S.; Nayebi, N.; Larijani, B.; Abdollahi, M. A systematic review of the efficacy and safety of herbal medicines used in the treatment of obesity. World J. Gastroenterol., 2009, 15(25), 3073-3085.
[http://dx.doi.org/10.3748/wjg.15.3073] [PMID: 19575486]
[74]
Bakhyia, N.; Dusemund, B.; Richter, K.; Lindtner, O.; Hirsch-Ernst, K.I.; Schäfer, B.; Lampen, A. [Risk assessment of synephrine in dietary supplements] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2017, 60(3), 323-331.
[http://dx.doi.org/10.1007/s00103-016-2506-5] [PMID: 28058460]
[75]
Haller, C.; Kearney, T.; Bent, S.; Ko, R.; Benowitz, N.; Olson, K. Dietary supplement adverse events: report of a one-year poison center surveillance project. J. Med. Toxicol., 2008, 4(2), 84-92.
[http://dx.doi.org/10.1007/BF03160960] [PMID: 18570167]
[76]
Hernandez, A. 3,5-diiodo-L-thyronine (t2) in dietary supplements: what are the physiological effects? Endocrinology, 2015, 156(1), 5-7.
[http://dx.doi.org/10.1210/en.2014-1933] [PMID: 25526549]
[77]
Kang, G.Y.; Parks, J.R.; Fileta, B.; Chang, A.; Abdel-Rahim, M.M.; Burch, H.B.; Bernet, V.J. Thyroxine and triiodothyronine content in commercially available thyroid health supplements. Thyroid, 2013, 23(10), 1233-1237.
[http://dx.doi.org/10.1089/thy.2013.0101] [PMID: 23758055]
[78]
Pye, K.G.; Kelsey, S.M.; House, I.M.; Newland, A.C. Severe dyserythropoiesis and autoimmune thrombocytopenia associated with ingestion of kelp supplements. Lancet, 1992, 339(8808), 1540.
[http://dx.doi.org/10.1016/0140-6736(92)91305-R] [PMID: 1351210]
[79]
Eliason, B.C. Transient hyperthyroidism in a patient taking dietary supplements containing kelp. J. Am. Board Fam. Pract., 1998, 11(6), 478-480.
[http://dx.doi.org/10.3122/jabfm.11.6.478] [PMID: 9876004]
[80]
Bürgi, H. Iodine excess. Best Pract. Res. Clin. Endocrinol. Metab., 2010, 24(1), 107-115.
[http://dx.doi.org/10.1016/j.beem.2009.08.010] [PMID: 20172475]
[81]
Astell, K.J.; Mathai, M.L.; Su, X.Q. Plant extracts with appetite suppressing properties for body weight control: a systematic review of double blind randomized controlled clinical trials. Complement. Ther. Med., 2013, 21(4), 407-416.
[http://dx.doi.org/10.1016/j.ctim.2013.05.007] [PMID: 23876572]
[82]
Saunders, K.H.; Umashanker, D.; Igel, L.I.; Kumar, R.B.; Aronne, L. J. Obesity pharmacotherapy. Med. Clin. North Am., 2018, 102(1), 135-148.
[http://dx.doi.org/10.1016/j.mcna.2017.08.010] [PMID: 29156182]

Rights & Permissions Print Cite
Article Metrics
117
14
© 2024 Bentham Science Publishers | Privacy Policy